NO970625D0 - 17q-koblete bryst- og ovariekreft mottagelighetsgener - Google Patents

17q-koblete bryst- og ovariekreft mottagelighetsgener

Info

Publication number
NO970625D0
NO970625D0 NO970625A NO970625A NO970625D0 NO 970625 D0 NO970625 D0 NO 970625D0 NO 970625 A NO970625 A NO 970625A NO 970625 A NO970625 A NO 970625A NO 970625 D0 NO970625 D0 NO 970625D0
Authority
NO
Norway
Prior art keywords
ovarian cancer
breast
relates
human
diagnosis
Prior art date
Application number
NO970625A
Other languages
English (en)
Other versions
NO970625L (no
Inventor
Mark H Skolnick
David E Goldgar
Yoshio Miki
Jeff Swenson
Alexander Kamb
Keith D Harshman
Donna M Shattuck-Eidens
Sean V Tavtigian
Roger W Wiseman
Andrew P Futreal
Original Assignee
Myriad Genetics Inc
Us Health
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970625(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/487,002 external-priority patent/US5710001A/en
Priority claimed from US08/483,554 external-priority patent/US5747282A/en
Application filed by Myriad Genetics Inc, Us Health, Univ Utah Res Found filed Critical Myriad Genetics Inc
Publication of NO970625D0 publication Critical patent/NO970625D0/no
Publication of NO970625L publication Critical patent/NO970625L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
NO970625A 1994-08-12 1997-02-11 17q-koblete bryst- og ovariekreft mottagelighetsgener NO970625L (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28922194A 1994-08-12 1994-08-12
US30026694A 1994-09-02 1994-09-02
US30810494A 1994-09-16 1994-09-16
US34882494A 1994-11-29 1994-11-29
US40930595A 1995-03-24 1995-03-24
US48801195A 1995-06-07 1995-06-07
US08/487,002 US5710001A (en) 1994-08-12 1995-06-07 17q-linked breast and ovarian cancer susceptibility gene
US08/483,554 US5747282A (en) 1994-08-12 1995-06-07 17Q-linked breast and ovarian cancer susceptibility gene
PCT/US1995/010203 WO1996005307A2 (en) 1994-08-12 1995-08-11 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE

Publications (2)

Publication Number Publication Date
NO970625D0 true NO970625D0 (no) 1997-02-11
NO970625L NO970625L (no) 1997-04-14

Family

ID=27575337

Family Applications (2)

Application Number Title Priority Date Filing Date
NO970626A NO970626L (no) 1994-08-12 1997-02-11 Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft
NO970625A NO970625L (no) 1994-08-12 1997-02-11 17q-koblete bryst- og ovariekreft mottagelighetsgener

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO970626A NO970626L (no) 1994-08-12 1997-02-11 Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft

Country Status (15)

Country Link
EP (2) EP0705902B2 (no)
JP (1) JP3399539B2 (no)
CN (1) CN1159829A (no)
AT (2) ATE198623T1 (no)
AU (2) AU691958B2 (no)
CA (2) CA2196795C (no)
DE (2) DE69524182T3 (no)
DK (2) DK0699754T3 (no)
ES (2) ES2154712T5 (no)
FI (2) FI970514A (no)
GR (1) GR3035631T3 (no)
NO (2) NO970626L (no)
NZ (1) NZ291624A (no)
PT (2) PT699754E (no)
WO (2) WO1996005307A2 (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US6951721B2 (en) 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
US6307035B1 (en) 1996-08-02 2001-10-23 The Wistar Institute Of Anatomy And Biology BRCA1 associated polynucleotide (BAP-1) and uses therefor
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
CA2273051A1 (en) 1996-12-03 1998-06-11 Prasanna Athma Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
AU754748B2 (en) 1997-06-04 2002-11-21 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
EP1003779A1 (en) * 1997-07-07 2000-05-31 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US5994096A (en) * 1997-07-25 1999-11-30 Smithkline Beecham Corporation Regulator
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002071928A2 (en) * 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
FR2836919B1 (fr) * 2002-03-05 2004-07-09 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
EP1430081A2 (fr) * 2001-06-13 2004-06-23 Centre National De La Recherche Scientifique (Cnrs) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
FR2826012B1 (fr) * 2001-06-13 2003-09-26 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
CA2482806A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101037690B (zh) * 2006-03-16 2011-07-20 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN102171214B (zh) 2008-08-06 2015-06-24 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US20120028254A1 (en) * 2009-02-06 2012-02-02 Weidhaas Joanne B SNP Marker of Breast and Ovarian Cancer Risk
AR079774A1 (es) 2009-07-15 2012-02-22 Astrazeneca Ab Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
CN105525009B (zh) * 2016-01-26 2018-10-16 绍兴华因生物科技有限公司 检测杂合性brca1/2基因缺失的方法及所用引物
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
JOP20220008A1 (ar) 2019-07-19 2023-01-30 Astrazeneca Ab مثبطات parp1
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN113388680B (zh) * 2020-03-14 2023-07-04 复旦大学附属妇产科医院 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
KR102262529B1 (ko) * 2020-06-15 2021-06-09 연세대학교 산학협력단 Brca 변이성 난소암에 대한 진단 방법 및 이를 이용한 키트
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
BR112023006337A2 (pt) 2020-10-09 2023-05-09 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022271547A1 (en) 2021-06-21 2022-12-29 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
MX2024006039A (es) 2021-11-18 2024-06-04 Astrazeneca Uk Ltd Combinacion de conjugado de anticuerpo-farmaco e inhibidor selectivo de poli(adenosina-5'-difosfato-ribosa) polimerasa 1 (parp1).
AU2022422276A1 (en) 2021-12-21 2024-08-01 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
KR20240130087A (ko) 2021-12-28 2024-08-28 아스트라제네카 유케이 리미티드 항체-약물 접합체와 atr 저해제의 조합
WO2023175483A1 (en) 2022-03-16 2023-09-21 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody‑drug conjugate therapy
WO2023194525A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194530A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
WO1991009964A1 (en) * 1990-01-04 1991-07-11 The Johns Hopkins University Gene deleted in colorectal cancer of humans
JP3179481B2 (ja) * 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
AU1236092A (en) * 1991-01-04 1992-08-17 Baylor College Of Medicine Tumor susceptible non-human animals
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994000764A1 (en) * 1992-06-26 1994-01-06 THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
JP3399539B2 (ja) 2003-04-21
DK0699754T3 (da) 2001-02-26
ES2164136T3 (es) 2002-02-16
CA2196795A1 (en) 1996-02-22
CA2196795C (en) 2001-04-03
ES2164136T5 (es) 2009-02-16
DK0705902T3 (da) 2002-03-11
AU3321695A (en) 1996-03-07
EP0699754B1 (en) 2001-01-10
GR3035631T3 (en) 2001-06-29
JP2002502227A (ja) 2002-01-22
FI970515A0 (fi) 1997-02-07
EP0699754B2 (en) 2009-08-12
ATE209660T1 (de) 2001-12-15
DE69519834T2 (de) 2001-04-26
EP0705902B2 (en) 2008-08-06
FI970514A0 (fi) 1997-02-07
DE69524182T2 (de) 2002-05-29
WO1996005308A1 (en) 1996-02-22
ES2154712T3 (es) 2001-04-16
AU691958B2 (en) 1998-05-28
DE69524182D1 (de) 2002-01-10
CA2196790A1 (en) 1996-02-22
PT705902E (pt) 2002-05-31
ATE198623T1 (de) 2001-01-15
AU3242895A (en) 1996-03-07
PT699754E (pt) 2001-04-30
DE69524182T3 (de) 2009-07-09
NO970626L (no) 1997-04-14
FI970515A (fi) 1997-04-07
ES2154712T5 (es) 2009-12-14
EP0705902A1 (en) 1996-04-10
AU691331B2 (en) 1998-05-14
EP0705902B1 (en) 2001-11-28
NO970625L (no) 1997-04-14
WO1996005307A2 (en) 1996-02-22
FI970514A (fi) 1997-04-07
WO1996005307A3 (en) 1996-03-14
DE69519834D1 (de) 2001-02-15
EP0699754A1 (en) 1996-03-06
NZ291624A (en) 1998-07-28
DE69519834T3 (de) 2010-04-01
NO970626D0 (no) 1997-02-11
CN1159829A (zh) 1997-09-17
CA2196790C (en) 2000-10-10

Similar Documents

Publication Publication Date Title
NO970625D0 (no) 17q-koblete bryst- og ovariekreft mottagelighetsgener
DK0705903T3 (da) Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen
NO982785L (no) Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (en) Chromosome 13-linked breast cancer susceptibility gene
AU6473598A (en) Method for determining the presence of mutated brca protein
WO1998025125A3 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
DE69934107D1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application